The Epidiolex Effect: Will Other CBD Drugs Receive FDA and DEA Approval?
Freedom Leaf
OCTOBER 15, 2018
On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.
Let's personalize your content